^[1] Department of Justice, Office of Public Affairs, «GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data», lunes 2 de julio de 2012. Disponible en ​http://www.justice.gov/opa/pr/2012/July/12-civ-842.html. <<

^[2] «Glaxo executives cited in case now lead Sanofi, Actelion», Bloomberg News, 3 de julio de 2012. Disponible en ​http:/www.businessweek.com/news/2012-07-03/glaxo-executives-cited-in-case-now-leadsanofi-actelion. <<

^[3] «GSK ruling another failing, but will the industry learn?», Inpharm, 4 de julio de 2012. Disponible en ​http://www.inpharm.com/news/173307/gsk-ruling-another-failing-will-industry-learn. <<

^[4] «Glaxo Agrees to Pay $3 billion in Fraud Settlement», New York Times, 2 de julio de 2012. Disponible en ​http://www.nytimes.com/2012/07/O3/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html. <<

^[5] «Level playing field push to continue despite setback», Medicines Australia, 8 de diciembre de 2011. Disponible en ​http://medicinesaustralia.com.au/2011/12/08/leve-playing-field-push-to-continue-despite-setback/. <<

^[6] «Drug companies to Work with CCGS on care pathways and case finding under DH-backed scheme», Pulse, 28 de mayo de 2012. Disponible en ​http://www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/1402 9608/drug-companies-to-work-with-ccgs-on-care-pathways-and-case-finding-under-dh-backed-scheme. <<

^[7] Bosch, X., Esfandiari, B., McHenry, L., «Challenging Medical Ghostwriting in US Courts», PLoS Medicine, vol. 9, n.° 1, 24 de enero de 2012, el001163. <<